Diversity, Equity and Inclusion Within the ORA
The ORA leadership team recently developed a Diversity, Equity and Inclusion statement that was approved by the Board of Directors. We invite you to scroll down to the bottom of our homepage to […]
Updated ORA Position Statement: Biosimilar Switching
The ORA has recently updated its position statement on biosimilar switching. It is available here: Updated ORA Position Statement Biosimilar Switching […]
Greetings From the New ORA President!
Greetings! I’d like to introduce myself to you as the new President of the Ontario Rheumatology Association. I am very excited to be leading such an important professional association! I have been with […]
Drug Shortages Update – Message from the Canadian Rheumatology Association
The Canadian Rheumatology Association (CRA) has been recently notified by members across the country of shortages in certain medications that are integral to patient care. The CRA has previously responded to alerts […]
Lancet Study: Vaccine Effectiveness Amongst Ontario Patients With Immune-Mediated Inflammatory Diseases
The full article is available here: The Lancet Rheumatology […]
Ontario Science Table Guidelines for COVID Treatments & Other Important Links
Please note the following important links: Ontario Science Table Guidelines for COVID Treatments: https://covid19-sciencetable.ca/sciencebrief/clinical-practice-guideline-summary-recommended-drugs-and-biologics-in-adult-patients-with-covid-19-version-10-0/ COVID Assessment Centres: https://covid-19.ontario.ca/covid-19-test-and-testing-location-information#getting-a-clinical-assessment List of Sites Distributing Paxlovid: List of sites distributing Paxlovid – 2022-02-14 (2) […]
Actemra (Tocilizumab) Update
Please see the most up to date information on Actemra shortages: Actemra Update […]
The Journal of Rheumatology – Board of Directors Position Available
The Journal of Rheumatology is actively seeking to fulfill an open position on its Board of Directors for election at their June 2022 Annual General Meeting. The deadline to apply is January 31, […]
Fourth Dose Boosters of COVID-19 Vaccine – Update
It was announced on January 13, 2022, that immunocompromised individuals may begin booking appointments to receive their 4th dose of the COVID-19 vaccine. Here is some information and resources for your reference: – […]
Updated MoH Guidelines – Booster Shots for Immunocompromised Patients After Primary Series
On December 14, 2021, the Ministry of Health published updated guidelines on COVID-19 Vaccine Third Dose Recommendations.Highlights of changes:•Immunocompromised individuals who are eligible for a three-dose primary series may receive a booster dose ≥6 months […]